drugset / Trial / NCT00058539
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.
Timeline
- Start
- 2003-04
- Primary completion
- 2004-10
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | — | — |